Alto Neuroscience(ANRO) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights – Initiated Phase 2 study of ALTO-203 in patients with MDD and anhedonia-– – Reported positive Phase 1 data with transdermal formulation of novel PDE4 inhibitor, ALTO-101; achieved significantly greater drug exposure with improved tolerability compared to oral administration – – Patient enrollment on track across Phase 2b MDD studies for ALTO-100 and ALTO-300 – – Strong cash position of approximately $ ...